# A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure

> **NCT00294086** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 160 (—)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** valsartan 160 mg
- **DRUG:** valsartan 160 mg BID

## Key facts

- **NCT ID:** NCT00294086
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 160 (—)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294086, "A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00294086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*